We were once endorsing the Ozaki technique as Adapt treated pericardium has the perfect qualities for the high pressure environment of the Aortic valve. Part of the problem with this for us was marketing. We were selling a technique and not a product. Therefore, surgeons using this technique would require significant convincing and training. From what I understand Japanese surgeons have a legendary status and are notoriously hard to deal with.
The study and Coroneo deal was ceased at the same period during code red. It would have been a significant drain on resource and cost. Focus has been redirected on the products and procedures requiring unique shapes and sizes with a near term and real p value.
- Forums
- ASX - By Stock
- AVR
- Approval in Japan
Approval in Japan, page-19
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$18.11 |
Change
0.110(0.61%) |
Mkt cap ! $346.0M |
Open | High | Low | Value | Volume |
$18.00 | $18.11 | $17.81 | $18.36K | 1.019K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 13 | $18.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.15 | 354 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13 | 18.010 |
1 | 100 | 18.000 |
1 | 167 | 17.900 |
1 | 29 | 17.810 |
1 | 500 | 17.800 |
Price($) | Vol. | No. |
---|---|---|
18.150 | 354 | 2 |
18.170 | 188 | 2 |
18.180 | 22 | 1 |
18.320 | 23 | 1 |
18.500 | 43 | 1 |
Last trade - 12.01pm 08/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |